14-day Premium Trial Subscription Sign Up For FreeGet Free

BioSpecifics Technologies Corp Stock Forecast NASDAQ:BSTC

$88.53 (0%)

Volume: 0

Closed: Jan 14, 2022

Hollow Logo Score: 0.000

BioSpecifics Technologies Corp Stock Forecast

$88.53 (0%)

Volume: 0

Closed: Jan 14, 2022

Score Hollow Logo 0.000

BioSpecifics Technologies Corp Company Profile

35 Wilbur Street

Lynbrook NY 11563




BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE